ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Gallium-68

Also written as “[68Ga]Ga-OncoACP3”, “Bombesin (68Ga) labeled (BAY86-7548)” and “[68Ga]Ga DOTA-5G”.

In Novartis’s pipeline, Radioligand therapy target HER2. Its studies are mostly in Prostatic Neoplasms · Breast Neoplasms · Colorectal Neoplasms · Carcinoma, Renal Cell · Urinary Bladder Neoplasms, led by 11 companies.

Drug pageGallium-68: every studyMany companies study it; this page follows only the 17 they lead. All 54 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 15, 202217 company-led studies, 9 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Philogenits history only40 open or runningphase 1since Dec 15, 2022Dec 15, 2022none ahead
Novartis31 open or runningphase 3since Jan 26, 2024Mar 26, 2018Jan 26, 2029phase 1 · NCT07117214
Lantheusits history only21 open or runningphase 3since Sep 4, 2026Sep 17, 2010Sep 30, 2029phase 3 · NCT07831824
Antaros Medicalits history only11 open or runningearly phase 1since Aug 14, 2024Aug 14, 2024none ahead
Braccoits history only11 open or runningphase 2since Jun 30, 2026Jun 30, 2026Feb 2028phase 2 · NCT07702292
GE Healthcareits history only11 open or runningphase 3since Oct 9, 2025Oct 9, 2025Jun 2029phase 3 · NCT07219238
Lumara Bio Oncologicsits history only11 open or runningphase 2since Dec 21, 2022Dec 21, 2022Jun 2027phase 2 · NCT05706129
Lumina Pharmaceuticalsits history only11 open or runningearly phase 1since Aug 19, 2026Aug 19, 2026Sep 1, 2027early phase 1 · NCT07781852
Luminance Biosciencesits history only11 open or runningphase 1since Oct 29, 2026Oct 29, 2026Dec 31, 2027phase 1 · NCT07915297
Sanofiits history only10 open or runningphase 1since Nov 16, 2017Nov 16, 2017none ahead

Also a collaborator on its studies: Medpace and Fortrea.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2018First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT03490032 · 30 enrolled · United States
  2. Jan 26, 2024Phase 3 study in HypersensitivityNCT06240741 · 71 enrolled · Japan
  3. Jul 22, 2025Phase 1 study in Breast NeoplasmsNCT07117214 · 36 planned · Netherlands

Ahead

  1. Jan 26, 2029Primary completion: phase 1 study in Breast NeoplasmsNCT07117214

TargetBeta

“Radioligand therapy target HER2”the company's pipeline, read by Claude · source
“Radioligand therapy target FAP”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Lutetium-177Novartisphase 324

Studies

All 3 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07117214Breast Neoplasms · Netherlands1RecruitingJan 26, 202936
NCT06240741Hypersensitivity · Japan3CompletedDec 27, 202471
NCT03490032Prostatic Neoplasms · United States2CompletedAug 20, 201930

How it is read

Names in the registry

  • “[68Ga]Ga-OncoACP3”, 2 entries
  • “Bombesin (68Ga) labeled (BAY86-7548)”, 2 entries
  • “[68Ga]Ga DOTA-5G”, 1 entry
  • “[68Ga]-LNTH-2401”, 1 entry
  • “[68Ga]BED003”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.